Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care
Overview
Authors
Affiliations
Background: Lack of accessible laboratory infrastructure limits HIV antiretroviral therapy (ART) initiation, monitoring, and retention in many resource-limited settings. Point-of-care testing (POCT) is advocated as a mechanism to overcome these limitations. We executed a pragmatic, prospective, randomized, controlled trial comparing the impact of POCT vs. standard of care (SOC) on treatment initiation and retention in care.
Methods: Selected POC technologies were embedded at 3 primary health clinics in South Africa. Confirmed HIV-positive participants were randomized to either SOC or POC: SOC participants were venesected and specimens referred to the laboratory with patient follow-up as per algorithm (∼3 visits); POC participants had phlebotomy and POCT immediately on-site using Pima CD4 to assess ART eligibility followed by hematology, chemistry, and tuberculosis screening with the goal of receiving same-day adherence counseling and treatment initiation. Participant outcomes measured at recruitment 6 and 12 months after initiation.
Results: Four hundred thirty-two of 717 treatment eligible participants enrolled between May 2012 and September 2013: 198 (56.7%) SOC; 234 (63.6%) POC. Mean age was 37.4 years; 60.5% were female. Significantly more participants were initiated using POC [adjusted prevalence ratio (aPR) 0.83; 95% confidence interval (CI): 0.74 to 0.93; P < 0.0001], the median time to initiation was 1 day for POC and 26.5 days for SOC. The proportion of patients in care and on ART was similar for both arms at 6 months (47 vs. 50%) (aPR 0.96; 95% CI: 0.79 to 1.16) and 12 months (32 vs. 32%) (aPR 1.05; 95% CI: 0.80 to 1.38), with similar mortality rates. Loss to follow-up at 12 months was higher for POC (36% vs. 51%) (aPR 0.82; 95% CI: 0.65 to 1.04).
Conclusions: Adoption of POCT accelerated ART initiation but once on treatment, there was unexpectedly higher loss to follow-up on POC and no improvement in outcomes at 12 months over SOC.
Richterman A, Dorvil N, Rivera V, Bang H, Severe P, Lavoile K Open Forum Infect Dis. 2025; 12(2):ofaf031.
PMID: 39906320 PMC: 11793062. DOI: 10.1093/ofid/ofaf031.
Richterman A, Dorvil N, Rivera V, Bang H, Severe P, Lavoile K medRxiv. 2024; .
PMID: 38946994 PMC: 11213038. DOI: 10.1101/2024.06.19.24309189.
Labhardt N, Brown J, Sass N, Ford N, Rosen S Clin Infect Dis. 2023; 77(8):1176-1184.
PMID: 37229594 PMC: 10573746. DOI: 10.1093/cid/ciad317.
Muhula S, Gachohi J, Kombe Y, Karanja S PLoS One. 2022; 17(2):e0263663.
PMID: 35139118 PMC: 8827476. DOI: 10.1371/journal.pone.0263663.
Point-of-care CD4 testing: Differentiated care for the most vulnerable.
Spooner E, Reddy T, Mchunu N, Reddy S, Daniels B, Ngomane N J Glob Health. 2022; 12:04004.
PMID: 35136596 PMC: 8818294. DOI: 10.7189/jogh.12.04004.